AbbVie(ABBV) - 2025 Q1 - Quarterly Results

Form 8-K Filing: Financial Guidance Update This Form 8-K filing provides an update on preliminary Q1 2025 financial results, revised EPS guidance due to an IPR&D expense, and details related exhibits Results of Operations and Financial Condition AbbVie announced preliminary Q1 2025 results, highlighting an expected acquired In-Process Research and Development (IPR&D) and milestones expense of $248 million, consequently updating its full-year and Q1 2025 adjusted diluted EPS guidance to incorporate this impact, while noting that the results are not yet final - Preliminary Q1 2025 results are expected to include a pre-tax acquired IPR&D and milestones expense of $248 million, which will unfavorably impact both GAAP and adjusted non-GAAP diluted EPS by $0.13[5] Updated 2025 Adjusted Diluted EPS Guidance | Guidance Period | Updated Adjusted Diluted EPS Range | Notes | | :--- | :--- | :--- | | Q1 2025 | $2.34 - $2.38 | Includes $0.13/share impact from IPR&D expense | | Full-Year 2025 | $11.99 - $12.19 | Includes Q1 IPR&D expense; original guidance from Jan 31, 2025 excluded this | - The updated guidance does not reflect the impact from the licensing agreement with Gubra for GUB014295, as that transaction closed after the first quarter of 2025[6] Financial Statements and Exhibits The report includes Exhibit 99.1, which provides detailed guidance including the impact of the acquired IPR&D and milestones expense, and Exhibit 104 for XBRL data - The filing includes the following key exhibits: * Exhibit 99.1: Detailed guidance including the impact of acquired IPR&D and milestones expense * Exhibit 104: Cover page data formatted in Inline XBRL[10] Forward-Looking Statements The report contains forward-looking statements subject to risks and uncertainties, with AbbVie cautioning that actual results may differ materially and directing investors to its Form 10-K and other SEC filings for a detailed discussion of these risks, without undertaking an obligation to update these statements - Forward-looking statements are subject to risks including, but not limited to, challenges to intellectual property, competition, R&D difficulties, adverse litigation or government action, and changes in laws and regulations[9] - For more detailed information on risks and uncertainties, the company refers to Item 1A, 'Risk Factors,' of its 2024 Annual Report on Form 10-K and subsequent SEC filings[9]